Back to top
more

Amgen (AMGN)

(Real Time Quote from BATS)

$333.30 USD

333.30
646,085

+2.29 (0.69%)

Updated Aug 30, 2024 03:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

by Zacks Equity Research

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks

by Zacks Equity Research

The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

Amgen (AMGN) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Amgen (AMGN) closed the most recent trading day at $241.75, moving +0.1% from the previous trading session.

Alimera Sciences (ALIM) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Alimera Sciences (ALIM) delivered earnings and revenue surprises of -92.86% and 11.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

by Zacks Equity Research

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Amgen (AMGN) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Amgen (AMGN) closed at $238.48 in the latest trading session, marking a +0.73% move from the prior day.

Bristol Myers (BMY) Gets Approval of Psoriasis Drug in EU

by Zacks Equity Research

Bristol Myers' (BMY) Sotyktu gets approval from the European Commission to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.

Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks

by Zacks Equity Research

The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

Should You Invest in the VanEck Biotech ETF (BBH)?

by Zacks Equity Research

Sector ETF report for BBH

AbbVie (ABBV) Provides Clinical Updates on Inflammatory Drugs

by Zacks Equity Research

AbbVie???s (ABBV) two studies evaluating Skyrizi in ulcerative colitis and Rinvoq in systemic lupus erythematosus meet their primary endpoints.

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for IBB

Amgen (AMGN) Stock Moves -1.34%: What You Should Know

by Zacks Equity Research

In the latest trading session, Amgen (AMGN) closed at $229.83, marking a -1.34% move from the previous day.

Here's What is Driving Amgen (AMGN) Stock's Outperformance

by Zacks Equity Research

Amgen's (AMGN) key drugs like Prolia, Repatha and Otezla are driving sales. It is also rapidly advancing its robust pipeline.

Amgen (AMGN) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Amgen (AMGN) closed at $232.95, marking a -0.75% move from the previous day.

The Zacks Analyst Blog Highlights Alphabet, Tesla, Amgen, FedEx and Capital One Financial

by Zacks Equity Research

Alphabet, Tesla, Amgen, FedEx and Capital One Financial are part of the Zacks top Analyst Blog.

Mark Vickery headshot

Top Analyst Reports for Alphabet, Tesla & Amgen

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), Tesla, Inc. (TSLA) and Amgen Inc. (AMGN).

How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks

by Zacks Equity Research

The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?

Amgen (AMGN) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, Amgen (AMGN) closed at $234.90, marking a +1.87% move from the previous day.

Amgen (AMGN) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Amgen (AMGN) closed at $230.58 in the latest trading session, marking a -1.12% move from the prior day.

Should You Invest in the iShares Biotechnology ETF (IBB)?

by Zacks Equity Research

Sector ETF report for IBB

Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks

by Zacks Equity Research

The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

Esperion Therapeutics (ESPR) Down 24% in a Week: Here's Why

by Zacks Equity Research

Shares of Esperion Therapeutics (ESPR) fell last week as the company's cardiovascular outcome CLEAR study results failed to meet investor expectations.

Amgen (AMGN) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Amgen (AMGN) closed the most recent trading day at $228.43, moving -0.13% from the previous trading session.

How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks

by Zacks Equity Research

The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

Amgen (AMGN) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Amgen (AMGN) closed the most recent trading day at $234.74, moving -0.61% from the previous trading session.